このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

OSIMERTINIB PLUS CAPIVASERTIB IN NSCLC WITH PIK3CA/AKT1/PTEN ALTERATIONS FOLLOWING PRIOR 1L OSIMERTINIB (Precision)

2026年11月18日 更新者:Shanxi Province Cancer Hospital

EGFR変異陽性進行非小細胞肺癌(NSCLC)患者における、ファーストラインオシメルチニブ単剤療法または化学療法併用療法後に進行したPIK3CA/AKT1/PTEN変異を有する患者を対象としたオシメルチニブ併用カピバセルチブの安全性と有効性:初回ヒト投与、フェーズIb/IIa試験(PRECISION)

The goal of this clinical trial is to learn if Osimertinib plus Capivasertib works to treat EGFRm advanced non-small cell lung cancer (NSCLC) in participants with PIK3CA/AKT1/PTEN alterations after progression on first-line Osimertinib (monotherapy or plus chemotherapy).

The main questions it aims to answer are:

Part A:

  • Number of Dose-limiting toxicities (DLTs)
  • Adverse events (AEs)/serious adverse events (SAEs) (graded by CTCAE Version 5.0)
  • Recommended combined dose (RCD)

Part B:Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria.

Participants will:

Part A:Take Capivasertib twice daily from day 1 to 4 of a 7-day cycle, Osimertinib will be given orally QD(once daily) at 80 mg throughout the study treatment period.

Part B: Take Osimertinib (80mg QD, continuously) and Capivasertib(RCD,orally BID from day1-day 4 in 7-day cycle , 4 days on /3 days off) till disease progression (PD) or unacceptable toxicity.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

This is a two-stage study, consisting of Phase Ib dose-escalation, Phase IIa dose expansion. Safety will be intensively monitored in Part A. If RCD (Recommended combined dose) was not reached in Part A, Part B (dose expansion phase) would not be initiated. If RCD was reached in Part A, eligible patients in Part B will be enrolled and receive Osimertinib (80mg QD, continuously) plus Capivasertib (RCD, orally BID from day1-day 4 in 7-day cycle , 4 days on /3 days off) till disease progression (PD) or unacceptable toxicity, with the aim to further evaluate the safety, tolerability and efficacy in terms of ORR, DCR, DOR, PFS and OS.

All participants (18 and above) will undergo screening (Day -28 to -1), treatment period (starting from Day 1) and post-intervention follow-up period (end of treatment visit, 30-day safety follow-up and survival follow-up).

Dose escalation(Part A) will follow the classic "3+3" schema. The DLT observation period is 28 days post first dose of study treatment. Dose escalation will occur only after DLT observation period is completed for a minimum of 3 participants, relevant data has been reviewed within the Safety Review Committee (SRC), and the SRC approves dose escalation.

研究の種類

介入

入学 (推定)

53

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国
        • Cancer Hospital Chinese Academy of Medical Sciences
        • コンタクト:
    • Shanxi
      • Taiyuan、Shanxi、中国
        • Shanxi Cancer Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion criteria

Informed consent

  1. Provision of signed and dated, written informed consent form (ICF) prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses

    Age

  2. Male or female age ≥18 years at the time of signing the ICF.

    Type of participant and disease characteristics

  3. Histologically or cytologically confirmed non-squamous locally advanced or metastatic NSCLC which is not amenable to curative therapy.

  4. Documented EGFR sensitive mutations (exon19 deletion, L858R mutation) prior to the first-line EGFR-TKI therapy.

  5. Documented radiologic progression on first-line treatment with Osimertinib monotherapy or Osimertinib plus chemotherapy:

    • Participants treated with Osimertinib in the adjuvant setting can be included if progression occurred < 6 months after last dose.
    • Participants must be immunotherapy (i.e., programmed cell death protein 1 [PD-1] inhibitor, programmed cell death protein 1 ligand 1 [PD-L1] inhibitor, Cytotoxic T-lymphocyte associated protein 4 inhibitor) naïve in the metastatic setting.
    • Prior immunotherapy in the neoadjuvant or adjuvant setting is acceptable providing treatment was completed more than 6 months before metastatic/recurrent disease was diagnosed.
  6. Mandatory provision of the required number of FFPE tumour tissue samples for PIK3CA mutations and/or AKT1 mutations and/or PTEN loss-of-function (LOF) mutations testing, which fulfils the following requirements:

    • Obtained following progression on previous Osimertinib monotherapy or Osimertinib plus chemotherapy as first-line treatment.
    • Specimen to meet the requirements defined in the Central Laboratory Manual and Diagnostic Testing Manual.
    • Have PIK3CA and/or AKT1 and/or PTEN alterations as determined by NGS testing by a sponsor designated central laboratory on tumour specimen collected following progression on prior Osimertinib treatment.
  7. At least one lesion, not previously irradiated, not biopsied during the screening period, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with CT or MRI, which is suitable for accurate repeated measurements. If only one measurable lesion exists, it is acceptable to be used if baseline tumour assessment scans are done at least 14 days after the screening tumour specimen collection is performed.

  8. Adequate bone marrow reserve and organ function as follows:

    • Absolute neutrophils count (ANC) ≥1.5x109/L.
    • Platelets count ≥100x109/L.
    • Haemoglobin (Hb) ≥90g/L.
    • Total bilirubin ≤1.5 times upper limit of normal (ULN) or ≤3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases.
    • Alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5ULN (or ≤5 ULN in the presence of liver metastases).
    • Creatinine clearance (CrCl) ≥50 ml/min (measured by 24hr urine output or calculated by Cockcroft and Gault equation).
  9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

  10. Patients with hepatitis B virus (HBV) are only eligible for inclusion if they meet all the following criteria:

    • Demonstrated absence of hepatitis C virus (HCV) co-infection or history of HCV co-infection
    • Demonstrated absence of human immunodeficiency virus (HIV) infection
    • Participants with active HBV infection are eligible if they are:
    • Receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to <100 IU/mL and transaminase levels are below ULN.
    • Participants with a resolved or chronic HBV infection are eligible if they are:
    • Negative for HBsAg and positive for hepatitis B core antibody [anti-HBc IgG or total anti-HBc Ab]. In addition, patients should be referred to a local hepatologist and treated as per local guidelines.

    or

    • Positive for HBsAg, but for > 6 months have had transaminases levels below ULN and HBV DNA levels below <100 IU/mL or below the detectable limit of locally available test kit (i.e., are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment.

    Patients with HIV are only eligible for inclusion if they meet all the following criteria:

    • Demonstrated absence of HBV/ HCV co-infection
    • Undetectable viral RNA load for 6 months
    • CD4+ count of >350 cells/µL
    • No history of AIDS-defining opportunistic infection within the past 12 months

    Stable for at least 4 weeks on the same anti-HIV medications.

  11. Ability to swallow and retain oral medications.

  12. Willingness and ability to comply with study and follow-up procedures. Reproduction

  13. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:

    • Post-menopausal defined as aged 50 years or more and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments.
    • Women under 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution.
    • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

    Further information in Appendix C (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods).

  14. Male participants must be willing to use barrier contraception.

Exclusion criteria

Medical conditions

  1. Patients harbouring concurrent actionable driver mutations with locally approved targeted therapies (e.g., MET amplification) will be excluded.

  2. Past medical history of ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.

  3. Clinically significant abnormalities of glucose metabolism as defined by any of the following:

    • Fasting glucose ≥7.0 mmol/L (126 mg/dL) or 2 hours after glucose solution intake, blood glucose ≥11.1 mmol/L (200 mg/dL).
    • HbA1c ≥8.0% (63.9 mmol/mol) at screening. Note: for any patient with evidence of impaired glucose control or insulin resistance refer to the Capivasertib Toxicity Management Guidelines.
  4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection (e.g. patients receiving treatment for infection) including hepatitis C and human immunodeficiency virus (HIV), or active uncontrolled hepatitis B virus (HBV) infection, or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice) .

    • Screening for chronic conditions is not required.

  5. Spinal cord compression, leptomeningeal metastasis, or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.

  6. Any of the following cardiac criteria:

    • Mean resting corrected QTc >470 msec, obtained from triplicate electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value.

    • History of QT prolongation associated with other medications that required discontinuation of that medication.

    • Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g., complete left bundle branch block, third degree heart block and second-degree heart block.

    • Medical history significant for arrhythmia (e.g., multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (Common Terminology Criteria for Adverse Events [CTCAE] Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted to enter the study based on the Investigator judgement with cardiologist consultation recommended.

    • Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities, heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes:

      • Patients with hypokalaemia|* ≥ CTCAE Grade 2 at screening are excluded.
      • - Hypomagnesaemia and hypocalcaemia are acceptable at screening if ≤ CTCAE Grade 1. Values > Grade 1 for magnesium or calcium should be corrected to ≤ Grade 1 prior to first dose, with documentation of the correction attempt.
    • Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) Grade 2.

  7. History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥2 years before the first dose of investigational product (IP) and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease.

  8. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment except for alopecia and grade 2 prior platinum-therapy related neuropathy. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the Investigator may be included (e.g., hearing loss).

  9. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of IP.

  10. Any other disease, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.

    Prior/concomitant therapy

  11. Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.

  12. Prior or current treatment with any PI3K/AKT pathway inhibitors, including but not limited to: Capivasertib or other AKT inhibitors, PI3K inhibitors, or agents targeting key nodes in this pathway (e.g., PTEN-modulating therapies).

  13. Concurrent use of herbal or natural products intended as treatment or prophylaxis for any type of cancer.

  14. Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study intervention or has not recovered from side effects of such therapy.

  15. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study. Procedures such as placement of vascular access, biopsy via mediastinoscopy or biopsy via video assisted thoracoscopic surgery (VATS) are permitted.

  16. Systemic therapy: Prior exposure to any anti-cancer agents other than those specified in the protocol (e.g. hormonal therapy such as luteinizing hormone releasing hormone [LHRH] agonists) without appropriate washout period before enrolment, for example, enrolment within 3 half-lives of a small molecule anti-cancer agent, or within 4 weeks for any antibody-based anticancer agents.

  17. Participants who are currently taking strong CYP3A4 inducers and cannot discontinue them at least 3 weeks before the first study dose must be excluded (Appendix B). This is because strong CYP3A4 inducers can decrease the exposure of osimertinib.Any concomitant medication that may interfere with Osimertinib safety and efficacy based on the prescribing information of Osimertinib and local clinical guidelines.

    Prior/concurrent clinical study experience

  18. Participation in another clinical study with a study intervention or investigational medicinal device administered in the 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

    Other exclusions

  19. History of hypersensitivity to active or inactive excipients of Capivasertib or Osimertinib or drugs with a similar chemical structure or class.

  20. Women who are currently pregnant (confirmed with positive pregnancy test) or breast-feeding or planning to become pregnant.

  21. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Capivasertib 320/400 mg in combination with Osimertinib 80mg

Capivasertib 320/400 mg (twice daily from day 1 to 4 of a 7-day cycle ),Osimertinib 80 mg( once daily continuously),28 days per cycle

Capivasertib 320/400 mg(twice daily from day 1 to 4 of a 7-day cycle ),Osimertinib 80 mg(once daily continuously),28 days per cycle

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
パートA 有害事象(AEs)/重篤な有害事象(SAEs)(CTCAEバージョン5.0によるグレード付け)
時間枠:インフォームドコンセント文書署名時から最大44ヶ月間
インフォームドコンセント文書署名時から最大44ヶ月間
Part A Number of Dose-limiting toxicities (DLTs)
時間枠:28 days post first dose of study treatment

A DLT is defined as any toxicity related to study drug and not attributable to the disease or disease-related processes under investigation, which occurs from the first dose of study treatment (Day 1, Cycle 0) up to the last day of Cycle 1 (28 days after start of dosing)

28 days post first dose of study treatment
Part A Recommended combined dose (RCD)
時間枠:From first dose of study treatment up to 12 months

The RCD is defined as the optimal dose combination of study drugs, established based on integrated assessment of safety and relevant available data from dose escalation phase

From first dose of study treatment up to 12 months
Part B Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria
時間枠:5 months post first dose of study treatment

ORR is defined as the percentage of participants who have at least one confirmed response of CR or PR prior to any evidence of progression (as determined by investigator at local site per RECIST 1.1)

5 months post first dose of study treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
パートB 有害薬物反応(ADR)
時間枠:インフォームド・コンセント同意書署名時から28か月まで
インフォームド・コンセント同意書署名時から28か月まで
Part A Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria
時間枠:5 months post first dose of study treatment

Confirmed ORR as defined in Primary Outcome Measure 4

5 months post first dose of study treatment
Part B Progression-free survival(PFS)
時間枠:From first dose of study treatment up to 27 months

PFS is defined as the time from initiation of study treatment to the date of objective disease progression or death (by any cause in the absence of progression), which occurs first, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression

From first dose of study treatment up to 27 months
Part B Duration of response(DoR )
時間枠:From 1 months post first dose of study treatment up to 27 months

DOR will be defined as the time from the date of first documented response (which is subsequently confirmed), until date of documented progression or death in the absence of disease progression

From 1 months post first dose of study treatment up to 27 months
Part B Disease control rate(DCR)
時間枠:From 2 months post first dose of study treatment up to 27 months

Disease control rate is defined as the proportion of patients with a best overall response of confirmed CR, confirmed PR, or SD

From 2 months post first dose of study treatment up to 27 months
Part B Overall survival(OS)
時間枠:From first dose of study treatment up to 27 months

Overall survival is defined as the time from the date of initiation of study treatment until death due to any cause

From first dose of study treatment up to 27 months
Part B AE/SAE
時間枠:From the time of signature of informed consent form up to 28 months

Number of participants with adverse events (AEs) according to CTCAE 5.0

From the time of signature of informed consent form up to 28 months
Part B Adverse events of special interest(AESI)
時間枠:From the time of signature of informed consent form up to 28 months

AESIs are events of scientific and medical interest specific to the further understanding of the safety profile of Capivasertib plus Osimertinib when given in combination and require close monitoring and rapid communication by the investigators to AstraZeneca. An AESI can be serious or nonserious

From the time of signature of informed consent form up to 28 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月8日

一次修了 (推定)

2029年5月15日

研究の完了 (推定)

2029年7月31日

試験登録日

最初に提出

2026年2月25日

QC基準を満たした最初の提出物

2026年3月17日

最初の投稿 (実際)

2026年3月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月18日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ESR-25-22924

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。